Viracta Therapeutics, Inc. Common Stock
VIRX
VIRX was delisted on the 3rd of February, 2025.
102 hedge funds and large institutions have $316M invested in Viracta Therapeutics, Inc. Common Stock in 2014 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 41 increasing their positions, 28 reducing their positions, and 11 closing their positions.
157% more call options, than puts
Call options by funds: $10.9M | Put options by funds: $4.26M
64% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 11
46% more repeat investments, than reductions
Existing positions increased: 41 | Existing positions reduced: 28
7% more funds holding
Funds holding: 95 → 102 (+7)
0% less capital invested
Capital invested by funds: $317M → $316M (-$1.03M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
+$6.44M |
| 2 |
NIP
Nicholas Investment Partners
Rancho Santa Fe,
California
|
+$1.71M |
| 3 |
Stifel Financial
St. Louis,
Missouri
|
+$1.35M |
| 4 |
U
UBS
Zurich,
Switzerland
|
+$1.29M |
| 5 |
PCM
Palisade Capital Management
Fort Lee,
New Jersey
|
+$1.26M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$5.14M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.59M |
| 3 |
PC
PointState Capital
New York
|
-$2.31M |
| 4 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$1.28M |
| 5 |
EI
EAM Investors
Solana Beach,
California
|
-$1.07M |
VIRX Hedge Fund Activity: Q2 2014 in Review
102 of the 3,480 institutional investors tracked by Wall St. Rank reported a position in Viracta Therapeutics, Inc. Common Stock (VIRX) for Q2 2014, worth a combined $316M — down 0.32% from $317M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new VIRX positions and 11 closed out — a net gain of 7 holders — while 41 added to existing stakes and 28 trimmed.
The largest buyer was Eagle Asset Management, opening a new position worth an estimated $6.44M. The largest seller was Farallon Capital Management, cutting an estimated $5.14M.
- 102 institutional investors held Viracta Therapeutics, Inc. Common Stock (VIRX) as of Q2 2014, up from 95 in Q1 2014.
- Funds reported $316M of Viracta Therapeutics, Inc. Common Stock stock for Q2 2014, down 0.32% quarter-over-quarter.
- 18 funds opened new Viracta Therapeutics, Inc. Common Stock positions in Q2 2014 and 11 closed out, a net change of +7 holders.
- The largest Viracta Therapeutics, Inc. Common Stock buyer in Q2 2014 was Eagle Asset Management, an estimated $6.44M added.
- The largest Viracta Therapeutics, Inc. Common Stock seller in Q2 2014 was Farallon Capital Management, an estimated $5.14M sold.
Based on aggregated 13F filings for Q2 2014.